Interleukin-33 (IL-33) is a new cytokine of interleukin-1 family, whose specific receptor is ST2. IL-33 exerts its functions via its target cells and plays different roles in diseases. ST2 deletion and exclusion of IL-33/ST2 axis are accompanied by enhanced susceptibility to dominantly T cell-mediated organ-specific autoimmune diseases. It has been reported that IL-33/ST2 pathway plays a key ro...

A detailed description of the simultaneous type, serial token (ST2) model is presented. ST2 is a model of temporal attention and working memory that encapsulates 5 principles: (a) M. M. Chun and M. C. Potter's (1995) 2-stage model, (b) a Stage 1 salience filter, (c) N. G. Kanwisher's (1987, 1991) types-tokens distinction, (d) a transient attentional enhancement, and (e) a mechanism for associat...

OBJECTIVES The aim of this study was to examine the value of measurement of the interleukin-1 receptor family member ST2 in patients with dyspnea. BACKGROUND Concentrations of ST2 have been reported to be elevated in patients with heart failure (HF). METHODS Five hundred ninety-three dyspneic patients with and without acute destabilized HF presenting to an urban emergency department were ev...

BACKGROUND ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF). We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Trainin...

Interleukin-1 receptor like 1 (ST2) is a negative regulator of Toll-like receptor (TLR) signaling. TLRs are important for host defense during respiratory tract infections by both influenza and Streptococcus (S.) pneumoniae. Enhanced susceptibility to pneumococcal pneumonia is an important complication following influenza virus infection. We here sought to determine the role of ST2 in primary in...

BACKGROUND No plasma biomarkers are associated with the response of acute graft-versus-host disease (GVHD) to therapy after allogeneic hematopoietic stem-cell transplantation. METHODS We compared 12 biomarkers in plasma obtained a median of 16 days after therapy initiation from 10 patients with a complete response by day 28 after therapy initiation and in plasma obtained from 10 patients with...